Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 1,578,800 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bvf Partners P/Il sold 1,578,800 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the sale, the director owned 240,123 shares of the company’s stock, valued at approximately $25,573,099.50. The trade was a 86.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Kymera Therapeutics Stock Down 7.2%

Shares of NASDAQ:KYMR traded down $8.34 on Friday, hitting $108.12. The company had a trading volume of 4,263,183 shares, compared to its average volume of 755,772. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $130.05. The firm has a market capitalization of $8.89 billion, a price-to-earnings ratio of -30.29 and a beta of 2.02. The firm’s 50-day simple moving average is $84.43 and its two-hundred day simple moving average is $82.12.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. During the same period in the previous year, the firm posted ($0.82) EPS. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 EPS for the current year.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera completed enrollment in its Phase 2b BROADEN2 trial for KT-621 ahead of schedule, accelerating the timeline for topline data to year-end 2026 and lifting optimism about the atopic dermatitis program. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
• Positive Sentiment: BTIG Research reaffirmed a buy rating on Kymera Therapeutics and set a $134 price target, reinforcing bullish expectations for the stock. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
• Neutral Sentiment: Kymera appointed Felix J. Baker, Ph.D. as chairman of the board, a leadership change that supports oversight but is less likely to move shares on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D. as Chairman of the Board of Directors
• Negative Sentiment: Recent insider selling, including shares sold by Noah Goodman and multiple sales by director Bruce Booth, may raise some caution despite being tied to a pre-arranged trading plan. Article: Insider transaction filing

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC boosted its stake in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares during the period. Larson Financial Group LLC lifted its position in shares of Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the period. Osaic Holdings Inc. boosted its position in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Kymera Therapeutics during the 4th quarter valued at about $63,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Kymera Therapeutics during the 2nd quarter worth approximately $73,000.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. BTIG Research reaffirmed a “buy” rating and issued a $134.00 target price on shares of Kymera Therapeutics in a report on Thursday. Loop Capital set a $97.00 target price on Kymera Therapeutics in a research report on Monday, June 8th. Citigroup upped their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Morgan Stanley reiterated an “overweight” rating and set a $119.00 price objective on shares of Kymera Therapeutics in a report on Thursday, April 30th. Finally, Jefferies Financial Group started coverage on Kymera Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $110.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $118.18.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.